NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=109172&from=3 CLASS PERIOD: January 23, 2023 to July 1 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Acadia Healthcare between February 28, 2020 and September 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW Y ...

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., October 19, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=108709&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=108480&from=3 CLASS PERIOD: January 23, 2023 to July 1 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEWS ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107867&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=107506&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid ...

文章核心观点 - 公司Agenus Inc.(NASDAQ: AGEN)的投资者在2023年1月23日至2024年7月17日期间购买了公司股票,并可能成为集体诉讼的原告 [1][2] - 根据指控,公司在该期间发布了虚假和/或误导性的信息,隐瞒了其免疫肿瘤产品botensilimab和balstilimab联合疗法的实际疗效低于预期的事实 [2] - 因此,公司对这些产品的临床结果、监管和商业前景的表述都被夸大了 [2] 公司相关 - 公司Agenus Inc.是一家生物制药公司,主要从事免疫肿瘤产品的研发 [2] - 公司的两款主要产品是botensilimab和balstilimab,这两款产品的联合疗法被指疗效低于预期 [2] - 公司在2023年1月23日至2024年7月17日期间发布了虚假和/或误导性信息,隐瞒了上述事实 [2] 投资者诉讼相关 - 投资者在2023年1月23日至2024年7月17日期间购买了公司股票,可能成为集体诉讼的原告 [1][2] - 投资者需在2024年11月5日之前登记,参与此次集体诉讼 [2] - 参与此次诉讼不需要任何费用或义务 [2]